INX-315, an Oral, Potent and Selective CDK2 Inhibitor in Patients with CDK4/6 Inhibitor Resistant ER+/HER2-Breast Cancer or CCNE1 Amplified Solid Tumors

Antoinette R. Tan, MD, MHSc⁽¹⁾; Antonio Giordano, MD, PhD⁽²⁾; Catherine Shannon,
MD⁽³⁾; Carey Anders, MD⁽⁴⁾; Nashat Gabrail, MD⁽⁵⁾; Kevin Kalinsky, MD, MS⁽⁶⁾; Patrick
Roberts, PharmD, PhD⁽⁷⁾; Andrew Beelen, MD⁽⁷⁾; George Au-Yeung, MD, PhD⁽⁸⁾

⁽¹⁾Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, ⁽²⁾Dana-
Farber Cancer Institute, ⁽³⁾Mater Hospital, ⁽⁴⁾Duke Cancer Center, ⁽⁵⁾Gabrail Cancer Center
Research, (6)Emory Winship Cancer Institute, ⁽⁷⁾Incyclix Bio, LLC, ⁽⁸⁾Peter MacCallum Cancer Center